ALK, ALK receptor tyrosine kinase, 238

N. diseases: 519; N. variants: 41
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE To investigate the relations between anaplastic lymphoma kinase (<i>ALK</i>) and v-myc myelocytomatosis viral related oncogene neuroblastoma derived homolog (<i>MYCN</i>) protein expression and their prognostic roles in neuroblastoma tumours. 31542727 2020
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Altogether, this study provides novel insights into ALK mutation dynamics in a neuroblastoma model harbouring two ALK mutations. 31452835 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE We review the basic aspects of MYCN, Trk, and ALK in both neural development and in neuroblastoma. 30848386 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 AlteredExpression disease BEFREE IHC confirmed the diagnosis by detecting the expression of ALK protein.After ALK positivity was proven, the effectiveness and safety of the crizotinib therapy was examined in 4 patients (1 alveolar rhabdomyosarcoma (RMA), 1 embryonal rhabdomyosarcoma (RME), 1 inflammatory myofibroblastic tumor (IMT), 1 NBL). 29081033 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE Mechanisms of acquired resistance to ALK inhibition therapy in neuroblastoma have not yet been elucidated. 31614113 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Surprisingly, thoracic neuroblastomas were more likely to harbor ALK driver mutations than adrenal cases among all cases (odds ratio = 1.89, 95% confidence interval = 1.04 to 3.43), and among cases without MYCN amplification (odds ratio = 2.86, 95% confidence interval = 1.48 to 5.49). 30793172 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE The Anaplastic Lymphoma Kinase (<i>ALK</i>) gene is frequently altered in NB, through copy number alterations and activating mutations, and represents a predisposition in NB-genesis when mutated. 31058082 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. 30538293 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas. 31419130 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE The results suggest that alectinib is an effective inhibitor of ALK kinase activity in ALK addicted neuroblastoma and should be considered as a potential future therapeutic option for ALK-positive neuroblastoma patients alone or in combination with other treatments. 31334113 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE ALK-amplified NBs were correlated with synchronous MYCN amplification and chromosome 1p deletion. 28326957 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE These data demonstrate that ALK is a bona fide immunotherapeutic target and provide a rationale for clinical development of an ALK-ADC approach for neuroblastomas and other ALK-expressing childhood cancers such as rhabdomyosarcomas. 30867324 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 AlteredExpression disease BEFREE ALK overexpression and activation, in the absence of genetic mutation has also been described in NB. 31340081 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status. 31780656 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE Multiple therapeutic approaches are being used to target MYCN, ALK, and TrkB, as well as GD2, a surface antigen present on the surface of neuroblastoma tumor cells. 31092383 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Although expression of ALK F1174L resulted in enhanced proliferation of sympathetic ganglion progenitors and increased the size of the sympathetic ganglia, it was insufficient to cause neuroblastoma. 31218818 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE Through a case study of mutations in kinase domains of three proteins, namely, the anaplastic lymphoma kinase (ALK) in pediatric neuroblastoma patients, serine/threonine-protein kinase B-Raf (BRAF) in melanoma patients, and erythroblastic oncogene B 2 (ErbB2 or HER2) in breast cancer patients, we compare the two approaches above. 30982079 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links. 31043380 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Combined treatment with alectinib and vorinostat might be a novel therapeutic option for NB harboring the ALK R1275Q mutation. 31262882 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Three hotspot residues (F1174, F1245, and R1275) account for 85% of mutant ALK seen in neuroblastoma. 30778092 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE Resistance to ALK Inhibitors in Neuroblastoma Is Regulated by BORIS. 31420353 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Mutations in the Anaplastic lymphoma tyrosine kinase (ALK) gene are common in NB. 30605844 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE Since most cases are in children under the age of 2, understanding the role and regulation of ALK during neural crest development is an important goal in addressing neuroblastoma tumorigenesis. 30803032 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 Biomarker disease BEFREE Our study provides strong rationale for clinical trial of ALK-positive neuroblastoma using ibrutinib or the combination of ibrutinib and ALK inhibitors. 30013190 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.700 GeneticVariation disease BEFREE Alterations in anaplastic lymphoma kinase (<i>ALK</i>) gene are involved in neuroblastoma, lung cancer, and other malignancies, but its role in SCCP has not been documented. 29559559 2018